- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Halozyme Therapeutics Inc
+ Add to WatchlistHALO:US
7.9600 USD 0.0200 0.25%As of 20:10:00 ET on 05/17/2013.
Snapshot for Halozyme Therapeutics Inc (HALO)
| Open: | 8.4100 | Day's Range: | 7.8900 - 8.4900 | Volume: | 4,005,777 |
|---|---|---|---|---|---|
| Previous Close: | 7.9800 | 52wk Range: | 3.8600 - 9.9200 | 1-Yr Rtn: | +0.76% |
Key Statistics for HALO
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.5200 |
| Est. EPS (USD) (12/2013) | -0.5640 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 900.76 |
| Shares Outstanding (M) | 113.16 |
| 30 Day Average Volume | 1,313,208 |
| Price/Book (mrq) | 28.3187 |
| Price/Sale (ttm) | 19.1341 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/06/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for HALO
Company Profile & Key Executives for HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical company developing products for the diabetes, cancer, dermatology and drug delivery markets. The Company's platform technology is based on recombinant human hyaluronidase plus additional enzymes. Halozyme applies its technology to its proprietary programs and to partnerships with pharmaceutical companies.
| Gregory Ian Frost "Greg"President/CEO/Co-Founder | Kurt A GustafsonVP/CFO |
| James P ShafferVP/Chief Commercial Officer | H Michael Shepard "Mike"VP/Chief Scientific Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
HALO News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page